NCT01732224View on ClinicalTrials.gov

To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Spontaneous Reactivation of Hepatitis B
Interventions
DRUG

Tenofovir + Telbivudine

Tenofovir (300 mg/day) plus telbivudine (600 mg/day).

DRUG

Tenofovir

In tenofovir arm subjects will receive tenofovir (300 mg) once daily.

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT01732224 - To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B | Biotech Hunter | Biotech Hunter